A multicenter, randomized, double-blind, prospective study comparing the safety and efficacy of ABT-335 and rosuvastatin calcium combination therapy to ABT-335 and rosuvastatin calcium monotherapy in subjects with mixed dyslipidemia

Trial Profile

A multicenter, randomized, double-blind, prospective study comparing the safety and efficacy of ABT-335 and rosuvastatin calcium combination therapy to ABT-335 and rosuvastatin calcium monotherapy in subjects with mixed dyslipidemia

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2009

At a glance

  • Drugs Choline fenofibrate; Rosuvastatin
  • Indications Dyslipidaemias; Lipid metabolism disorders
  • Focus Registrational; Therapeutic Use
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Jun 2009 Results of a retrospective analysis were presented at the 69th annual meeting of the American Diabetes Association, according to a Abbott Laboratories media release.
    • 03 Jun 2008 Primary endpoints all met. Results presented at the American Society of Clinical Oncology (ASCO) 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top